跳转至内容
Merck
CN
  • Prefrontal cortical dendritic spine pathology in schizophrenia and bipolar disorder.

Prefrontal cortical dendritic spine pathology in schizophrenia and bipolar disorder.

JAMA psychiatry (2014-10-02)
Glenn T Konopaske, Nicholas Lange, Joseph T Coyle, Francine M Benes
摘要

Prior studies have demonstrated reduced dendritic spine density in the dorsolateral prefrontal cortex (DLPFC) in schizophrenia. However, it remains unclear how generalizable this finding is in schizophrenia and if it is seen in bipolar disorder, a historically distinct psychiatric condition. To assess whether spine loss is present in the DLPFC of individuals with schizophrenia and individuals with bipolar disorder. This study used postmortem human brain tissue from individuals with schizophrenia (n=14), individuals with bipolar disorder (n=9), and unaffected control participants (n=19). Tissue samples containing the DLPFC (Brodmann area 46) were Golgi-stained, and basilar dendrites of pyramidal cells in the deep half of layer III were reconstructed. The number of spines per dendrite, spine density, and dendrite length were compared across groups. We also assessed for the potential effects of clinical and demographic variables on dendritic parameters. The mean (SD) spine density was significantly reduced (ie, by 10.5%) in individuals with bipolar disorder (0.28 [0.04] spines/μm) compared with control participants (0.31 [0.05] spines/μm) (P=.02). In individuals with schizophrenia, the mean (SD) spine density was also reduced (by 6.5%; 0.29 [0.03] spines/μm) but just missed significance when compared with control participants (P=.06). There was a significant reduction in the mean (SD) number of spines per dendrite in both individuals with schizophrenia (72.8 [24.9] spines per dendrite) and individuals with bipolar disorder (68.9 [12.9] spines per dendrite) compared with controls (92.8 [31.1] spines per dendrite) (individuals with schizophrenia vs controls: 21.6% reduction [P=.003]; individuals with bipolar disorder vs controls: 25.8% reduction [P=.005]). In addition, both individuals with schizophrenia and individuals with bipolar disorder had a reduced mean (SD) dendrite length (246.5 [67.4] and 245.6 [29.8] μm, respectively) compared with controls (301.8 [75.1] μm) (individuals with schizophrenia vs controls: 18.3% reduction [P=.005]; individuals with bipolar disorder vs controls: 18.6% reduction [P=.005]). Dendritic spine loss in the DLPFC was seen in both individuals with schizophrenia and individuals with bipolar disorder, suggesting that the 2 disorders may share some common pathophysiological features.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
乙醇,Pure 200纯度, Molecular Biology
Sigma-Aldrich
纯乙醇, 200 proof, ACS reagent, ≥99.5%
Sigma-Aldrich
纯乙醇, 200 proof
Sigma-Aldrich
纯乙醇, 200 proof, meets USP testing specifications
Sigma-Aldrich
纯乙醇, 200 proof, anhydrous, ≥99.5%
Sigma-Aldrich
乙醇,Pure 190纯度, for molecular biology
Sigma-Aldrich
邻二甲苯, puriss. p.a., ≥99.0% (GC)
Sigma-Aldrich
纯乙醇, 190 proof, ACS spectrophotometric grade, 95.0%
Sigma-Aldrich
酒精, BioUltra, Molecular Biology, ≥99.8%, (absolute alcohol, without additive, A15 o1)
Sigma-Aldrich
邻二甲苯, reagent grade, ≥98.0%
Supelco
无水乙醇, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
纯乙醇, 190 proof, meets USP testing specifications
Supelco
酒精, standard for GC
Supelco
邻二甲苯, suitable for HPLC, 98%
Sigma-Aldrich
邻二甲苯, anhydrous, 97%
Sigma-Aldrich
氯氮平标准液
Sigma-Aldrich
酒精, puriss. p.a., absolute, ≥99.8% (GC)
Supelco
Ethanol 溶液, certified reference material, 2000 μg/mL in methanol
Supelco
邻二甲苯, analytical standard
Sigma-Aldrich
酒精, tested according to Ph. Eur.
Supelco
10% (v/v) 乙醇标准品, 10 % (v/v) in H2O, analytical standard
Sigma-Aldrich
氟哌啶醇, powder
USP
无水酒精, United States Pharmacopeia (USP) Reference Standard
Supelco
氯氮平标准液 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
Haloperidol solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
邻二甲苯, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
80% v/v 乙醇固定液, suitable for fixing solution (blood films)
USP
氯氮平标准液, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
纯乙醇, 190 proof, ACS reagent, meets USP testing specifications, Excise Tax-free, Permit for use required
USP
氟哌啶醇, United States Pharmacopeia (USP) Reference Standard